EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Targeting Lactylation Offers Therapy to Reverse Cell Death Resistance

Yumin Wang iD, Jinxia Chen, Yan Wang, Yuwei Cao, Yulin Li, Yonglin Zhu, Zhe Zhang, Shuang Wu, Hongquan Wang iD

Drug Design, Development and Therapy · 2025-12 · Volume 19 · 11371-11394

DOI: 10.2147/dddt.s567488 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025-12. Verfasst von Yumin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 10…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lactylation, a lactate-derived post-translational modification, emerges as a master metabolic regulator of resistance to regulated cell death (RCD) across pathologies including cancer, inflammatory disorders, and degenerative diseases. By dynamically modifying histones and non-histone proteins via lactyltransferases and delactylases, lactylation orchestrates convergent molecular pathways that suppress ferroptosis, cuproptosis, and apoptosis. This review synthesizes current understanding of lactylation as a central regulator of RCD resistance in diseases, especially in cancers. We dissect the molecular machinery through which lactylation subverts ferroptosis, cuproptosis, and apoptosis; evaluate its pathophysiological implications in diverse pathologies; and discuss emerging therapeutic strategies to disrupt lactylation-mediated cell death evasion. This metabolic-epigenetic crosstalk establishes a robust shield against RCD in disease microenvironments, promoting therapeutic resistance and pathological resilience. Targeting lactylation regulators (writers/erasers) or combining lactate modulation with RCD inducers represents a promising strategy to overcome treatment-refractory conditions in cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansAnimalsProtein Processing, Post-TranslationalFerroptosisApoptosisCell Death

Stichwörter der Autor:innen

apoptosiscuproptosisferroptosislactylationregulated cell death

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 100049, People's Republic of China.
  • Department of Blood Transfusion, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China.
  • Hunan Provincial Key Laboratory of Hepatobiliary Disease Research & Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, People…
  • Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, 430000, People's Republic of China.
  • Department of Geriatrics, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 100049, People's Republic of China.
  • Aerospace Medical Center, Aerospace Center Hospital, Beijing, 100049, People's Republic of China.

ORCID-Profile: Yumin Wang, Hongquan Wang

Zitieren

APA

Wang, Y., Chen, J., Wang, Y., Cao, Y., Li, Y., Zhu, Y., Zhang, Z., Wu, S., & Wang, H. (2025). Targeting Lactylation Offers Therapy to Reverse Cell Death Resistance. Drug Design, Development and Therapy, Volume 19, 11371-11394. https://doi.org/10.2147/dddt.s567488

Vancouver

Wang Y, Chen J, Wang Y, Cao Y, Li Y, Zhu Y, et al. Targeting Lactylation Offers Therapy to Reverse Cell Death Resistance. Drug Design, Development and Therapy. 2025;Volume 19:11371-11394. doi:10.2147/dddt.s567488

BibTeX
@article{Wang2025,
  author = {Wang, Yumin and Chen, Jinxia and Wang, Yan and Cao, Yuwei and Li, Yulin and Zhu, Yonglin and Zhang, Zhe and Wu, Shuang and Wang, Hongquan},
  title = {Targeting Lactylation Offers Therapy to Reverse Cell Death Resistance},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {11371--11394},
  doi = {10.2147/dddt.s567488}
}
Kostenlos starten →